Tel: +65 6601 2348
The main focus of Dr Chen Leilei’s group is to study the transcriptome instability of human cancers, particularly hepatocellular carcinoma (HCC), the major malignancy of the liver and the third leading cause of cancer-related deaths globally. While the epidemiological risk factors for HCC are well known, the molecular mechanisms underlying development of liver cancer are not well characterized. It is especially important to understand the potentially reversible epigenetic mechanisms, since these changes are novel candidates for therapeutic targeting. One type of epigenetic change is RNA editing, defined as an alteration of RNA sequences. Using integrative genomic approaches, her group recently highlighted a link between transcriptome instabilities in the form of excessive or defective RNA editing activity and cancer development. She currently places focus on the regulators of A-to-I RNA editing and the crosstalk between RNA editing and alternative splicing-the two main processes contributing to transcriptome diversity. This work will provide important insights into the regulation of tumorigenesis by transcriptome instability, in turn translating these findings into diagnoses or even treatment.